ABL Bio Shares Plunge After Sanofi Reprioritizes Development

The market has been shaken by news that Sanofi, the global partner of ABL Bio, has reprioritized the development of 'ABL301,' a candidate treatment for Parkinson's disease. ABL Bio clarified that this is a strategic realignment unrelated to discontinuation of development or changes to the contract.

On the morning of January 30, ABL Bio's stock price fell by around 15% in early trading, with investor sentiment rapidly freezing. This was a result of Sanofi announcing on January 29 (local time), during its fourth-quarter earnings release, that ABL301 has been classified as a target for "deprioritization." While the asset has not been completely removed from the pipeline, it is now perceived as having stepped back from its previous position as a core asset that would receive the company's resources first in the short term.

원본보기 아이콘

With this reprioritization, analysts believe that instead of proceeding directly to Phase 2 clinical trials as originally anticipated, Sanofi is likely to revise its strategy by conducting an additional Phase 1b trial. The market views the uncertainty around the timing of milestone payments, due to delays in the clinical timeline, as the direct cause of the stock price decline.

ABL Bio responded immediately. The company stated, "We have received an official response from Sanofi that this is neither a contract termination nor a discontinuation of development," emphasizing that this is a strategic adjustment to increase the likelihood of clinical success. The company also stressed that this decision is unrelated to its own blood-brain barrier (BBB) shuttle platform, 'Grabody-B.'

Industry experts point to the difficulty of validating the 'alpha-synuclein' target, a key challenge in developing Parkinson's disease treatments, as the background for the reprioritization of ABL301. Although alpha-synuclein is known to be a major causative agent of Parkinson's disease, it is extremely challenging to clinically prove that removing it actually leads to improvement in patients' symptoms. In fact, global pharmaceutical companies such as Biogen and Roche have also struggled to demonstrate clear efficacy in clinical trials targeting the same antibody.

It is also analyzed that Sanofi has chosen to reevaluate its strategy through a Phase 1b trial rather than hastily moving to Phase 2. The company is reportedly seeking an approach that involves further segmenting patient groups and introducing advanced analytical techniques, such as cerebrospinal fluid and imaging analysis, to first confirm whether the drug actually acts on alpha-synuclein pathology.

The academic community also continues to point out that it is difficult to assess drug efficacy in Parkinson's disease development based solely on symptom changes. Recently, biomarker-based validation showing how precisely a drug modulates its target within the brain has emerged as a key factor for clinical success. A research team at the University of Cambridge in the UK emphasized in a paper published in the medical journal 'Journal of Neurology' in 2024 that precise measurement of target occupancy through high-sensitivity biomarker analysis is essential.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.